OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-2.77%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$535M
AUM Growth
+$535M
(-11%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
2.38%
Top 10 Holdings %
Top 10 Hldgs %
59.08%
Holding
57
New
9
Increased
13
Reduced
14
Closed
9
Top Buys
| 1 |
Semler Scientific
SMLR
|
$28.2M |
| 2 |
Keros Therapeutics
KROS
|
$4.65M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$4.24M |
| 4 |
Amicus Therapeutics
FOLD
|
$3.06M |
| 5 |
CMRX
Chimerix, Inc.
CMRX
|
$2.48M |
Top Sells
| 1 |
ESSA Pharma
EPIX
|
$8.12M |
| 2 |
Seres Therapeutics
MCRB
|
$5.96M |
| 3 |
GeneDx Holdings
WGS
|
$5.24M |
| 4 |
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
|
$3.82M |
| 5 |
Kezar Life Sciences
KZR
|
$3.79M |
Sector Composition
| 1 | Healthcare | 98.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $64.8M | 12.1% | 6,480,000 | – | – |
|
2
Celldex Therapeutics
CLDX
$1.47B
| $53M | 9.91% | 985,000 | – | – |
|
3
Codexis
CDXS
$246M
| $31.3M | 5.84% | 1,345,000 | – | – |
|
|
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
| $31.1M | 5.82% | 5,030,000 +400,000 | +9% | +$2.48M |
|
5
Harrow
HROW
$1.44B
| $29.9M | 5.58% | 3,285,000 +145,000 | +5% | +$1.32M |
|
|
6
Semler Scientific
SMLR
$439M
| $28.2M | 5.27% | +225,566 | New | +$28.2M |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $24M | 4.48% | 511,500 -5,650 | -1% | -$265K |
|
8
Cytokinetics
CYTK
$4.23B
| $20.7M | 3.87% | 580,000 | – | – |
|
9
Protara Therapeutics
TARA
$120M
| $17.7M | 3.31% | 2,558,472 | – | – |
|
10
Eton Pharmaceutcials
ETON
$464M
| $15.6M | 2.91% | 3,088,100 -604,500 | -16% | -$3.05M |
|
11
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $14.9M | 2.79% | 1,310,000 +154,800 | +13% | +$1.76M |
|
|
12
Keros Therapeutics
KROS
$618M
| $13.9M | 2.6% | 352,500 +117,500 | +50% | +$4.65M |
|
13
Stereotaxis
STXS
$261M
| $13.6M | 2.54% | 2,526,500 | – | – |
|
14
Fortress Biotech
FBIO
$76.8M
| $12.1M | 2.26% | 3,750,000 -125,000 | -3% | -$403K |
|
15
ProQR Therapeutics
PRQR
$237M
| $11.9M | 2.23% | 1,424,200 +43,800 | +3% | +$367K |
|
16
Sutro Biopharma
STRO
$72.7M
| $10.2M | 1.9% | 537,800 +40,900 | +8% | +$773K |
|
|
TCON
17
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $9.75M | 1.82% | 2,518,371 | – | – |
|
18
MacroGenics
MGNX
$112M
| $9.67M | 1.81% | 462,000 -116,150 | -20% | -$2.43M |
|
19
Larimar Therapeutics
LRMR
$310M
| $9.6M | 1.79% | 832,807 +105,007 | +14% | +$1.21M |
|
20
Vaxcyte
PCVX
$4B
| $8.97M | 1.67% | 353,400 -4,400 | -1% | -$112K |
|
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.46M | 1.58% | 402,113 +201,613 | +101% | +$4.24M |
|
22
Xoma
XOMA
$392M
| $8.37M | 1.56% | 338,350 -5,250 | -2% | -$130K |
|
23
Neurogene
NGNE
$264M
| $7.57M | 1.41% | 1,047,300 -108,900 | -9% | -$787K |
|
|
ADMS
24
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $7.17M | 1.34% | 1,460,000 -210,600 | -13% | -$1.03M |
|
25
Verastem
VSTM
$569M
| $7.16M | 1.34% | 2,325,000 | – | – |
|